Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Yu, H. A. [1 ]
Cantero, F. [2 ]
Kim, B. [3 ]
Lee, M. [4 ]
Wu, E. [5 ]
Sternberg, D. W. [6 ]
Janne, P. A. [7 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA
[3] Daiichi Sankyo Inc, Clin Sci, Basking Ridge, NJ USA
[4] Daiichi Sankyo Inc, Quantitat Clin Pharmacol, Basking Ridge, NJ USA
[5] Daiichi Sankyo Inc, Biostat, Basking Ridge, NJ USA
[6] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA
[7] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1313
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1190TiP
引用
收藏
页码：S1092 / S1093
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
    Janne, Pasi A.
    Baik, Christina S.
    Su, Wu-Chou
    Johnson, Melissa Lynne
    Hayashi, Hidetoshi
    Nishio, Makoto
    Kim, Dong-Wan
    Koczywas, Marianna
    Gold, Kathryn A.
    Steuer, Conor Ernst
    Murakami, Haruyasu
    Yang, James Chih-Hsin
    Kim, Sang-We
    Vigliotti, Michele
    Qi, Zhenhao
    Qiu, Yang
    Zhao, Lihui
    Sternberg, David W.
    Yu, Channing
    Yu, Helena Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
    Janne, Pasi A.
    Baik, Christina
    Su, Wu-Chou
    Johnson, Melissa L.
    Hayashi, Hidetoshi
    Nishio, Makoto
    Kim, Dong-Wan
    Koczywas, Marianna
    Gold, Kathryn A.
    Steuer, Conor E.
    Murakami, Haruyasu
    Yang, James Chih-Hsin
    Kim, Sang-We
    Vigliotti, Michele
    Shi, Rong
    Qi, Zhenhao
    Qiu, Yang
    Zhao, Lihui
    Sternberg, David
    Yu, Channing
    Yu, Helena A.
    CANCER DISCOVERY, 2022, 12 (01) : 74 - 89
  • [3] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer (vol 12, pg 74, 2022)
    Janne, P. A.
    Baik, C.
    Su, W. C.
    Johnson, M., I
    Hayashi, H.
    Nishio, M.
    CANCER DISCOVERY, 2022, 12 (06) : 1598 - 1598
  • [4] Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
    Steuer, Conor Ernst
    Hayashi, Hidetoshi
    Su, Wu-Chou
    Nishio, Makoto
    Johnson, Melissa Lynne
    Kim, Dong-Wan
    Koczywas, Marianna
    Felip, Enriqueta
    Gold, Kathryn A.
    Murakami, Haruyasu
    Baik, Christina S.
    Kim, Sang-We
    Smit, Egbert F.
    Gigantone, Mark
    Kim, Ben
    Fan, Pang-Dian
    Qi, Zhenhao
    Wu, Elaine Y.
    Sternberg, David W.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without EGFR-Activating Mutations
    Johnson, M. L.
    Steuer, C. E.
    Hayashi, H.
    Su, W. -C.
    Nishio, M.
    Kim, D. -W.
    Koczywas, M.
    Felip, E.
    Gold, K. A.
    Murakami, H.
    Baik, C. S.
    Kim, S. -W.
    Smit, E. F.
    Gigantone, M.
    Kim, B.
    Fan, P. -D.
    Qi, Z.
    Wu, E. Y.
    Sternberg, D.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E30 - E31
  • [6] Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
    Yu, H.
    Baik, C.
    Gold, K.
    Hayashi, H.
    Johnson, M.
    Koczywas, M.
    Murakami, H.
    Nishio, M.
    Steuer, C.
    Su, W.
    Yang, J. C.
    Karam, S.
    Qi, Z.
    Qiu, Y.
    Chen, S.
    Yu, C.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S107 - S107
  • [7] HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
    Yu, Helena A.
    Yang, James Chih-Hsin
    Hayashi, Hidetoshi
    Goto, Yasushi
    Felip, Enriqueta
    Reck, Martin
    Vigliotti, Michele
    Dong, Qian
    Cantero, Frederique
    Fan, Pang-Dian
    Kanai, Masayuki
    Sternberg, David W.
    Jaenne, Pasi A.
    FUTURE ONCOLOGY, 2023, 19 (19) : 1319 - 1329
  • [8] Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
    Yu, H. A.
    Goto, Y.
    Hayashi, H.
    Felip, E.
    Yang, J. C. -H.
    Reck, M.
    Yoh, K.
    Lee, S. -H.
    Paz-Ares, L.
    Besse, B.
    Bironzo, P.
    Kim, D. -W.
    Johnson, M. L.
    Wu, Y. -L.
    Vigliotti, M.
    Dong, Q.
    Fan, P. -D.
    Shrestha, P.
    Sternberg, D. W.
    Sellami, D.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S53 - S54
  • [9] Dynamics of Molecular Markers in EGFR-Mutated NSCLC Patients Treated with Patritumab Deruxtecan (HER3-DXd; U3-1402)
    Janne, P.
    Baik, C.
    Hayashi, H.
    Su, W.
    Qi, Z.
    Enomoto, K.
    Karnoub, M.
    Yu, C.
    Qiu, Y.
    Yu, H. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S237 - S237
  • [10] Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
    Yu, H. A.
    Baik, C.
    Kim, D. -W.
    Johnson, M. L.
    Hayashi, H.
    Nishio, M.
    Yang, J. C. -H.
    Su, W. -C.
    Gold, K. A.
    Koczywas, M.
    Smit, E. F.
    Steuer, C. E.
    Felip, E.
    Murakami, H.
    Kim, S. -W.
    Su, X.
    Sato, S.
    Fan, P. -D.
    Fujimura, M.
    Tanaka, Y.
    Patel, P.
    Sternberg, D. W.
    Sellami, D.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2024, 35 (05) : 437 - 447
12345